Myriva Quinolones

Moxifloxacin is a fourth generation fluoroquinolone: an inhibitor of bacterial topoisomerase IV and DNA gyrase with expanded activity against gram-positive bacteria as well as atypical pathogens. 


Myriva Moxifloxacin (as HCL) 400 mg

  • Adults

    Type of Infection

    Dose Every 24 hours

    Duration (days)

    Community Acquired Pneumonia

    400 mg


    Complicated Skin and Skin Structure Infections (SSSI)

    400 mg


    Pelvic Inflammatory Disease

    400 mg


    Acute Bacterial Sinusitis

    400 mg


    Acute Exacerbation of Chronic Bronchitis

    400 mg


     Moxifloxacin is contraindicated in children and adolescents (< 18 years). Efficacy and safety of moxifloxacin in children and adolescents have not been established

    • Hypersensitivity to moxifloxacin, other quinolones or to any of the excipients.
    • Pregnancy and lactation
    • Patients below 18 years of age.
    • Patients with a history of tendon disease/disorder related to quinolone treatment.
    • Congenital or documented acquired QT prolongation
    • Electrolyte disturbances, particularly in uncorrected hypokalaemia
    • Clinically relevant bradycardia
    • Clinically relevant heart failure with reduced left-ventricular ejection fraction
    • Previous history of symptomatic arrhythmias
    • Moxifloxacin should not be used concurrently with other drugs that prolong the QT interval.
    • Patients with impaired liver function.